Skip to main content

Table 2 Simulation results for evaluating a prognostic biomarker in the setting of the E1900 trial

From: Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies

Biomarker Treatment Measure of Association Relative Efficiency Relative Cost-Efficiency
    RS-2 RS-3 GT-2 GT-3 RS-2 RS-3 GT-2 GT-3
FLD3-ITD HD log-OR 0.61 0.38 0.87 0.76 1.22 1.13 1.75 2.29
log-ratio 0.57 0.34 0.87 0.76 1.15 1.03 1.74 2.26
difference 0.60 0.37 0.87 0.76 1.19 1.12 1.75 2.29
SD log-OR 0.50 0.33 0.82 0.65 1.01 0.98 1.65 1.94
log-ratio 0.49 0.31 0.83 0.66 0.98 0.94 1.65 1.97
difference 0.51 0.34 0.83 0.65 1.02 1.01 1.65 1.96
DNMT3A HD log-OR 0.64 0.41 0.89 0.80 1.27 1.23 1.79 2.40
log-ratio 0.60 0.39 0.89 0.78 1.20 1.17 1.78 2.33
difference 0.61 0.41 0.89 0.78 1.23 1.22 1.78 2.35
SD log-OR 0.50 0.33 0.85 0.71 1.00 1.00 1.70 2.13
log-ratio 0.50 0.33 0.85 0.70 0.99 0.99 1.70 2.11
difference 0.51 0.34 0.85 0.71 1.01 1.03 1.71 2.13